Read by QxMD icon Read


shared collection
15 papers 25 to 100 followers
By Faye Kehler Family Physician and GP Anesthetist since 1987 interested in all aspects of Medicine
S Clare Stanford
Both psychostimulants and antidepressants target monoamine transporters and, as a consequence, augment monoamine transmission. These two groups of drugs also increase motor activity in preclinical behavioural screens for antidepressants. Substance P-preferring receptor (NK1R) antagonists similarly increase both motor activity in these tests and monoamine transmission in the brain. In this article, the neurochemical and behavioural responses to these three groups of drugs are compared. It becomes evident that NK1R antagonists represent a distinct class of compounds ('motor disinhibitors') that differ substantially from both psychostimulants and antidepressants, especially during states of heightened arousal or stress...
December 2014: Neuropharmacology
Natalie B V Riblet, Brian Shiner, Yinong Young-Xu, Bradley V Watts
Background Few randomised controlled trials (RCTs) have shown decreases in suicide. Aims To identify interventions for preventing suicide. Method We searched EMBASE and Medline from inception until 31 December 2015. We included RCTs comparing prevention strategies with control. We pooled odds ratios (ORs) for suicide using the Peto method. Results Among 8647 citations, 72 RCTs and 6 pooled analyses met inclusion criteria. Three RCTs ( n = 2028) found that the World Health Organization (WHO) brief intervention and contact (BIC) was associated with significantly lower odds of suicide (OR = 0...
June 2017: British Journal of Psychiatry: the Journal of Mental Science
Pierre-Michel Llorca, Christophe Lançon, Ann Hartry, T Michelle Brown, Dana B DiBenedetti, Siddhesh A Kamat, Clément François
BACKGROUND: Treatment of schizophrenia and major depressive disorder (MDD) with atypical antipsychotics (AAPs) show improved efficacy and reduced side effect burden compared with older antipsychotic medications. However, a risk of treatment-emergent adverse events (TEAEs) remains. TEAEs are hard to quantify and perspectives on the importance of TEAEs differ across patients and between patients and physicians. The current study is a qualitative assessment that investigates TEAEs of AAPs from both patient and physician perspectives to provide better understanding of the occurrence and burden of TEAEs associated with these medications...
February 13, 2017: BMC Psychiatry
Gerard Sanacora, Mark A Frye, William McDonald, Sanjay J Mathew, Mason S Turner, Alan F Schatzberg, Paul Summergrad, Charles B Nemeroff
Importance: Several studies now provide evidence of ketamine hydrochloride's ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders. Observations: This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge...
April 1, 2017: JAMA Psychiatry
Susan L McElroy, Anna Guerdjikova, Renu Kotwal, Jeffrey A Welge, Erik B Nelson, Kathleen A Lake, Paul E Keck, James I Hudson
OBJECTIVE: Binge-eating disorder (BED) is associated with obesity. Atomoxetine is a highly selective norepinephrine reuptake inhibitor associated with weight loss. The purpose of this study was to evaluate atomoxetine in the treatment of BED. METHOD: In this 10-week, single-center, randomized, double-blind, placebo-controlled, flexible dose (40-120 mg/day) trial, outpatients with DSM-IV-TR BED received atomoxetine or placebo. The primary outcome measure was binge-eating episode frequency...
March 2007: Journal of Clinical Psychiatry
Marianna Mazza, Giuseppe Marano, Luigi Janiri
No abstract text is available yet for this article.
October 2016: Expert Opinion on Pharmacotherapy
I Kelleher
No abstract text is available yet for this article.
July 2016: Acta Psychiatrica Scandinavica
Charles W Hoge, Rachel Yehuda, Carl A Castro, Alexander C McFarlane, Eric Vermetten, Rakesh Jetly, Karestan C Koenen, Neil Greenberg, Arieh Y Shalev, Sheila A M Rauch, Charles R Marmar, Barbara O Rothbaum
No abstract text is available yet for this article.
July 1, 2016: JAMA Psychiatry
Luis H Ripoll, Joseph Triebwasser, Larry J Siever
Patients with personality disorders are prescribed psychotropic medications with greater frequency than almost any other diagnostic group. Prescribing practices in these populations are often based on anecdotal evidence rather than rigorous data. Although evidence-based psychotherapy remains an integral part of treatment, Axis II psychopathology is increasingly conceptualized according to neurobiological substrates that correspond to specific psychopharmacological strategies. We summarize the best available evidence regarding medication treatment of personality disordered patients and provide optimal strategies for evidence-based practice...
October 2011: International Journal of Neuropsychopharmacology
Saeed Shoja Shafti, Hamid Kaviani
INTRODUCTION: Around 40-60% of the patients with obsessive-compulsive disorder (OCD) remain unimproved by serotonin reuptake inhibitors (SRIs). Goal of this study was to compare the efficiency and safety of aripiprazole versus quetiapine, in patients with OCD, who did not respond effectively to fluvoxamine. METHOD: A total of 44 female inpatients with OCD, who did not respond successfully to fluvoxamine at maximum dose (300 mg/day) and duration (12 weeks), were assigned randomly, in a double-blind trial, to receive aripiprazole (n = 22) or quetiapine (n = 22), in addition to their SRI, for 12 weeks...
February 2015: Therapeutic Advances in Psychopharmacology
Marie Naughton, Gerard Clarke, Olivia F O'Leary, John F Cryan, Timothy G Dinan
INTRODUCTION: Recent research has seen low-dose ketamine emerge as a novel, rapid-acting antidepressant. Ketamine, an N-methy-d-aspartate (NMDA) receptor antagonist, leads to effects on the glutamatergic system and abnormalities in this neurotransmittor system are present in depression. This article aims to (1) review the clinical literature on low-dose ketamine as a rapid-acting antidepressant in affective disorders, (2) provide a critical overview of the limitations of ketamine and research attempts to overcome these (3) discuss the proposed mechanisms of action of ketamine and (4) point towards future research directions...
March 2014: Journal of Affective Disorders
Martin A Katzman, Pierre Bleau, Pierre Blier, Pratap Chokka, Kevin Kjernisted, Michael Van Ameringen, Martin M Antony, Stéphane Bouchard, Alain Brunet, Martine Flament, Sophie Grigoriadis, Sandra Mendlowitz, Kieron O'Connor, Kiran Rabheru, Peggy M A Richter, Melisa Robichaud, John R Walker
BACKGROUND: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated. METHODS: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012)...
2014: BMC Psychiatry
Borwin Bandelow, Leo Sher, Robertas Bunevicius, Eric Hollander, Siegfried Kasper, Joseph Zohar, Hans-Jürgen Möller
OBJECTIVE: Anxiety disorders are frequently under-diagnosed conditions in primary care, although they can be managed effectively by general practitioners. METHODS: This paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) for the treatment in primary care. The recommendations were developed by a task force of 30 international experts in the field and are based on randomized controlled studies...
June 2012: International Journal of Psychiatry in Clinical Practice
Borwin Bandelow, Joseph Zohar, Eric Hollander, Siegfried Kasper, Hans-Jürgen Möller, Joseph Zohar, Eric Hollander, Siegfried Kasper, Hans-Jürgen Möller, Borwin Bandelow, Christer Allgulander, José Ayuso-Gutierrez, David S Baldwin, Robertas Buenvicius, Giovanni Cassano, Naomi Fineberg, Loes Gabriels, Ian Hindmarch, Hisanobu Kaiya, Donald F Klein, Malcolm Lader, Yves Lecrubier, Jean-Pierre Lépine, Michael R Liebowitz, Juan José Lopez-Ibor, Donatella Marazziti, Euripedes C Miguel, Kang Seob Oh, Maurice Preter, Rainer Rupprecht, Mitsumoto Sato, Vladan Starcevic, Dan J Stein, Michael van Ameringen, Johann Vega
In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs...
2008: World Journal of Biological Psychiatry
Naomi A Fineberg, Samar Reghunandanan, Helen B Simpson, Katharine A Phillips, Margaret A Richter, Keith Matthews, Dan J Stein, Jitender Sareen, Angus Brown, Debbie Sookman
This narrative review gathers together a range of international experts to critically appraise the existing trial-based evidence relating to the efficacy and tolerability of pharmacotherapy for obsessive compulsive disorder in adults. We discuss the diagnostic evaluation and clinical characteristics followed by treatment options suitable for the clinician working from primary through to specialist psychiatric care. Robust data supports the effectiveness of treatment with selective serotonin reuptake inhibitors (SSRIs) and clomipramine in the short-term and the longer-term treatment and for relapse prevention...
May 30, 2015: Psychiatry Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"